Article History
Received: 6 September 2023
Revised: 21 December 2023
Accepted: 10 March 2024
First Online: 3 April 2024
Competing interests
: NTNU and St. Olavs Hospital, Trondheim University Hospital may benefit financially from a commercialization of the ultrasound equipment through future possible intellectual properties; this may include financial benefits to authors of this article. H.T and S.A.N. are co‐inventors of NeoDoppler. S.A.N. is board member in CIMON medical, H.T. and S.A.N. have part time positions and are among shareholders in CIMON medical, the company that is responsible for commercialization of NeoDoppler. The technology used in this study is a prototype/research setup. G.D. and M.L.O. have nothing to disclose.
: Written informed consent was obtained from the parents of the participants.